AltheaDx to Offer the DxS K-RAS Test for Clinical Studies
News Nov 05, 2008
DxS Ltd has announced an agreement with US-based Oncology diagnostic and biopharmaceutical services company AltheaDx, Inc., which will provide US study centres with access to DxS’ K-RAS mutation detection assays.
The deal will see AltheaDx use DxS’s K-RAS Mutation Test Kit to support clinical research where cancer patients are assessed for their K-RAS mutation status.
The deal builds on DxS’ continued expansion this year with the exclusive global distribution agreement with Roche earlier this year. The deal also builds on the AltheaDx biomarker development collaboration with BiPar Sciences and Poniard Pharmaceuticals, and reinforces the position of AltheaDx as the premier biopharma partner for signature discovery, and companion diagnostic development.
The DxS K-RAS Mutation Test kit allows clinicians to screen patients for mutations in the K-RAS gene which is mutated in approximately 35-45% of metastatic colorectal cancer, as well as a variety of other cancers.
This year also saw further clinical data announced at the ASCO conference, which has led to a need for colorectal cancer patients to be screened for mutations in the K-RAS gene in order to identify the most appropriate treatment. Patients carrying mutations in the K-RAS gene do not respond to a class of drugs known as EGFR inhibitors – such as Vectibix® and Erbitux®.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019